AAN 2016 Multiple Sclerosis

The beneficial effects of Cladribine for relapsing-remitting multiple sclerosis (RRMS) patients have been demonstrated in a 120-week extension trial

Ozanimod (RPC1063), an oral selective S1P receptor modulator currently in development, has shown efficacy in reducing relapse rates in relapsing multiple sclerosis.

For patients with relapsing-remitting Multiple Sclerosis (RRMS), concomitant use of selective serotonin-reuptake inhibitors (SSRIs) and fingolimod, does not affect cardiac outcomes related to initiation of fingolimod.

For relapse-remitting MS patients with expanded disability status scale (EDSS) scores of >3, once-daily laquinimod 0.6mg can reduce annualized relapse rates (ARR) and confirmed disability progression (CDP).

No correlation between interferon treatment and antidepressant use was observed in the multiple sclerosis (MS) population, a large-scale study presented at the 68th AAN Annual Meeting reported.

An interim 4-year follow-up analysis of fingolimod (Gilenya) found the safety profile of the treatment to be consistent with the results of phase 3 clinical trials, researchers reported at the 68th Annual AAN Meeting.

Natalizumab use has been tied to a reduction in annual relapse rates (AAR) for patients with relapsing-remitting multiple sclerosis (RRMS).

Patients with relapse-onset multiple sclerosis (MS) who have reached disease steps 3, 4, or 6 should still receive highly effective immunomodulatory therapy to mitigate disability accrual.

The beneficial effects of oral propionate, an approved food additive, have been demonstrated in humans for the first time, according to a study presented at the 68th Annual AAN Meeting.

Lipoic acid is safe, well tolerated, and offers neuroprotection in patients with secondary progressive multiple sclerosis (MS), results from a “highly promising pilot study” presented at the 68th Annual AAN Meeting have shown.